Abstract
Background: CDK12 has emerged as an attractive cancer target due to its role in transcription and regulation of DNA repair. It has been proposed that the loss of CDK12 function is synthetic lethal with PARP inhibition. Here, we assessed the combination effect of Compound A, a potent and selective CDK12 inhibitor, with olaparib, a PARP1/2 inhibitor, in both BRCA WT and mutant models.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
